| Authors: |
Palumbo JM; Zynerba Pharmaceuticals Inc., Devon, PA, USA., Thomas BF; Empirical Pharmaceutical Services, LLC, Manteo, NC, USA., Budimirovic D; Departments of Psychiatry and Neurogenetics, Fragile X Clinic, Kennedy Krieger Institute, Baltimore, MD, USA.; Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA., Siegel S; Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Tassone F; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA, USA., Hagerman R; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA., Faulk C; Department of Animal Science, University of Minnesota, St. Paul, MN, USA., O'Quinn S; Zynerba Pharmaceuticals Inc., Devon, PA, USA. Oquinns@Zynerba.com., Sebree T; Zynerba Pharmaceuticals Inc., Devon, PA, USA. |
